Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) released its earnings results on Wednesday. The company reported ($4.88) earnings per share (EPS) for the quarter, Zacks reports.
Attovia Therapeutics Stock Performance
Shares of NASDAQ:ATTO traded up $0.91 during midday trading on Wednesday, hitting $23.13. 81,161 shares of the stock were exchanged, compared to its average volume of 262,593. Attovia Therapeutics has a 12 month low of $16.15 and a 12 month high of $24.32.
Analysts Set New Price Targets
A number of research analysts have recently commented on the stock. Citigroup started coverage on shares of Attovia Therapeutics in a report on Monday. They issued a “buy” rating and a $30.00 target price for the company. Lifesci Capital began coverage on shares of Attovia Therapeutics in a research report on Monday. They set an “outperform” rating and a $45.00 price objective for the company. Royal Bank Of Canada started coverage on shares of Attovia Therapeutics in a research note on Monday. They issued an “outperform” rating and a $45.00 price objective for the company. Leerink Partners started coverage on shares of Attovia Therapeutics in a research report on Monday. They issued an “outperform” rating and a $52.00 target price on the stock. Finally, Morgan Stanley assumed coverage on shares of Attovia Therapeutics in a research note on Monday. They set an “overweight” rating and a $39.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Attovia Therapeutics has an average rating of “Buy” and a consensus price target of $42.20.
Insiders Place Their Bets
In other Attovia Therapeutics news, Director Colin Walsh bought 500,000 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the transaction, the director directly owned 3,020,632 shares in the company, valued at approximately $51,350,744. This represents a 19.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Redmile Group, Llc bought 400,000 shares of Attovia Therapeutics stock in a transaction on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $6,800,000.00. Following the completion of the acquisition, the insider directly owned 1,182,854 shares in the company, valued at approximately $20,108,518. The trade was a 51.10% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 2,740,587 shares of company stock worth $47,269,979 over the last quarter.
Attovia Therapeutics Company Profile
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Featured Articles
- Five stocks we like better than Attovia Therapeutics
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Attovia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Attovia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
